Vimarsana
Biggest News Aggregation in the World

Page 19 - Specific Populations News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Specific Populations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Specific Populations Today - Breaking & Trending Today

Regeneron Reports Positive Interim Data with REGEN-COV™ Antibody Cocktail used as Passive Vaccine to Prevent COVID-19 - Vimarsana News

Regeneron Reports Positive Interim Data with REGEN-COV™ Antibody Cocktail used as Passive Vaccine to Prevent COVID-19

Reduction in overall infections seen within first week, with 100% prevention of symptomatic infections Markedly decreased levels and duration of viral shedding in asymptomatic infections that still occurred in REGEN-COV group Confirmatory Phase 3 results expected early in second quarter Potential application in people who need immediate protection or respond poorly to vaccination REGEN-COV 1,200 mg administered by subcutaneous injection, providing greater convenience and efficiency than infusion Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive initial results from a...

Biohaven Announces Preliminary 4Q2020 Net Product Revenue For NURTEC® ODT - Vimarsana News

Biohaven Announces Preliminary 4Q2020 Net Product Revenue For NURTEC® ODT

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV - Vimarsana News

Janssen Announces U.S. FDA Approval of CABENUVA (rilpivirine and cabotegravir), the First Long-Acting Regimen for the Treatment of HIV

Share this article Share this article TITUSVILLE, N.J., Jan. 21, 2021 /PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved CABENUVA (consisting of Janssen's rilpivirine and ViiV Healthcare's cabotegravir), the first and only once-monthly, long-acting regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults. The novel regimen was co-developed as part of a collaboration with ViiV Healthcare and builds on Janssen's 25-year commitment to make HIV history. In the U.S., ...

Regeneron Announces Encouraging Initial Data from COVID-19 Antibody Cocktail Trial in Hospitalized P - Vimarsana News

Regeneron Announces Encouraging Initial Data from COVID-19 Antibody Cocktail Trial in Hospitalized P

TARRYTOWN, N.Y., Dec. 29, 2020 /PRNewswire/ --Phase 3 program in hospitalized patients to continue based on passing futility analysis on ability to reduce incidence of death or mechanical ventilation As in earlier outpatient trial, immune status when patients entered the trial was a strong predictor of viral load...

Regeneron Announces Encouraging Initial Data from COVID-19 Antibody Cocktail Trial in Hospitalized Patients on Low-flow Oxygen - Vimarsana News

Regeneron Announces Encouraging Initial Data from COVID-19 Antibody Cocktail Trial in Hospitalized Patients on Low-flow Oxygen

Share this article TARRYTOWN, N.Y., Dec. 29, 2020 /PRNewswire/ -- Phase 3 program in hospitalized patients to continue based on passing futility analysis on ability to reduce incidence of death or mechanical ventilation As in earlier outpatient trial, immune status when patients entered the trial was a strong predictor of viral load and clinical outcomes First antibody therapy to demonstrate anti-viral effect in patients hospitalized with COVID-19 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced encouraging initial data from an ongoing Phase 1/2/3 clinical trial of the Regener...